Skip to main content
Top
Published in: The Journal of Obstetrics and Gynecology of India 6/2014

01-12-2014 | Original Article

Multicenter Study of Contraceptive Vaginal Ring (NuvaRing®) in Normal Daily Practice in Indian Women

Authors: Suchitra N. Pandit, Anahita R. Chauhan, Manjula Anagani, Sanjeeva Reddy, Ashish Birla, Subrat K. Ray

Published in: The Journal of Obstetrics and Gynecology of India | Issue 6/2014

Login to get access

Abstract

Objective

This was the first Indian multicenter study at six specialty hospitals, to assess the real-life usage of the vaginal ring in daily clinical practice.

Methods

This open-label, prospective, single-arm, nonrandomized, interventional study enrolled 252 women aged >18 years, seeking contraception with no contraindications to the use of combined hormonal contraceptive. Women were provided the ring with a monthly follow-up schedule for three cycles. Cycle control, acceptability, tolerability, and safety assessments were recorded at each visit.

Results

Regular menstrual bleeding was reported by 76.2 % (192/252) at baseline. In study completers, regular bleeding was seen in 94.1 % (192/204), 97.5 % (199/204), and 98 % (200/204) in the 1st, the 2nd, and the 3rd cycles, respectively. Most (94.2 % [195/207]) women were very satisfied or satisfied with the ring, and 93.2 % (193/207) would recommend it to others. No pregnancies or serious adverse events were reported.

Conclusion

The study demonstrated that NuvaRing® is a highly effective contraceptive method with an excellent cycle control. It is well tolerated and accepted by Indian women.
Literature
2.
go back to reference Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing®, compared with an oral contraceptive containing 30 µg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74:451–7.PubMedCrossRef Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing®, compared with an oral contraceptive containing 30 µg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74:451–7.PubMedCrossRef
3.
go back to reference Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect. 1998;30:89–92.PubMedCrossRef Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect. 1998;30:89–92.PubMedCrossRef
4.
go back to reference Soni A, Garg S, Bangar R. Efficacy, user acceptability, tolerability, and cycle control of a combined contraceptive vaginal ring: the Indian perspective. J Obstet Gynecol India. 2013;. doi:10.1007/sl3224-013-0391-5. Soni A, Garg S, Bangar R. Efficacy, user acceptability, tolerability, and cycle control of a combined contraceptive vaginal ring: the Indian perspective. J Obstet Gynecol India. 2013;. doi:10.​1007/​sl3224-013-0391-5.
6.
go back to reference Roumen FMJE, Apter D, Mulders TMT, et al. Efficacy, tolerability, and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyloestradiol. Hum Reprod. 2001;16:469–75.PubMedCrossRef Roumen FMJE, Apter D, Mulders TMT, et al. Efficacy, tolerability, and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyloestradiol. Hum Reprod. 2001;16:469–75.PubMedCrossRef
7.
go back to reference Dieben TOM, Roumen FMJE, Apter D. Efficacy, cycle control, and user acceptability of a novel contraceptive vaginal ring. Obstet Gynecol. 2002;100:585–92.PubMedCrossRef Dieben TOM, Roumen FMJE, Apter D. Efficacy, cycle control, and user acceptability of a novel contraceptive vaginal ring. Obstet Gynecol. 2002;100:585–92.PubMedCrossRef
8.
go back to reference Novak A, De la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing®: an international study for user acceptability. Contraception. 2003;67:187–94.PubMedCrossRef Novak A, De la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing®: an international study for user acceptability. Contraception. 2003;67:187–94.PubMedCrossRef
9.
go back to reference Roumen FMJE, op ten Berg MMT, Hoomans EHM. The combined contraceptive vaginal ring NuvaRing®: first experience in daily clinical practice in the Netherlands. Eur JContracept Reprod Health Care. 2006; 11:14–22. Roumen FMJE, op ten Berg MMT, Hoomans EHM. The combined contraceptive vaginal ring NuvaRing®: first experience in daily clinical practice in the Netherlands. Eur JContracept Reprod Health Care. 2006; 11:14–22.
10.
go back to reference Merki-Feld GS, Hund M. Clinical experience with NuvaRing® in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care. 2007;12:240–7.PubMedCrossRef Merki-Feld GS, Hund M. Clinical experience with NuvaRing® in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care. 2007;12:240–7.PubMedCrossRef
Metadata
Title
Multicenter Study of Contraceptive Vaginal Ring (NuvaRing®) in Normal Daily Practice in Indian Women
Authors
Suchitra N. Pandit
Anahita R. Chauhan
Manjula Anagani
Sanjeeva Reddy
Ashish Birla
Subrat K. Ray
Publication date
01-12-2014
Publisher
Springer India
Published in
The Journal of Obstetrics and Gynecology of India / Issue 6/2014
Print ISSN: 0971-9202
Electronic ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-014-0559-7

Other articles of this Issue 6/2014

The Journal of Obstetrics and Gynecology of India 6/2014 Go to the issue